Clinical trial · no report yet · Phase 3
iMMagine-3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
- NCT06413498 ↗
- Active, not recruiting
- Kite, A Gilead Company
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 26 | |
| YouTube | 13 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Anitocabtagene Autoleucel; Cyclophosphamide; Fludarabine; Pomalidomide; Bortezomib; Dexamethasone; Daratumumab; Carfilzomib
- Arms
- Anitocabtagene Autoleucel · Experimental
- Standard of Care Therapy (SOCT) · Active comparator
- Enrollment
- 452
- Primary outcomes
- Progression-Free Survival (PFS)
- Minimal Residual Disease (MRD) Complete Response (CR) Rate at 9 Months
- Sponsor
- Kite, A Gilead Company with Arcellx, Inc.
- Start
- Aug 23, 2024
- Primary completion
- Jul 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06413498 · updated Jul 29, 2026